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Background: Conventional models of carcinogenesis suggest that tumors recruit blood vessel formation from
normal host tissues. This concept has recently been challenged by prominent studies of glioblastoma, which
suggest that intratumoral endothelial cells (ECs) may arise from cancer stem cells/tumor-initiating cells (TICs).
Hepatocellular carcinoma (HCC) is a common, highly vascularized tumor with few effective therapies, against which
anti-angiogenic strategies are being actively explored. TICs are felt to play a role in HCC pathobiology, but their
contributions to tumor vasculature have not been studied.
Methods: We examined human HCCs in settings that selected for tumor formation from functionally defined TICs,
and in which the origin of intratumoral ECs from TICs as opposed to host tissues could be clearly distinguished. We
generated HCC nodules in the livers of immunodeficient mice by intrasplenic injection of HCC cells from cell lines
and patient specimens and studied the tumor ECs by immunohistochemistry for mouse and human markers. We
then used immunohistochemistry for EC markers in combination with fluorescence in situ hybridization (FISH) for X
and Y chromosomes to study the endothelium of recurrent HCC specimens resected from sex-mismatched liver
allografts of patients who had undergone liver transplantation for HCC.
Results: We observed that all ECs in intrahepatic human HCC xenografts expressed mouse rather than human
CD31. FISH analysis of recurrent HCCs resected from patients with sex-mismatched liver allografts revealed that all
CD31+ and CD34+ intratumoral ECs originated from the donor allograft rather than the tumor.
Conclusions: These observations suggest that the vasculature of human HCC arises from normal host tissues rather
than from TICs, supporting ongoing efforts to target angiogenesis in HCC as it is currently understood, and
suggesting that the contribution of TICs to the vasculature of other cancers is disease-specific.
Keywords: Hepatocellular carcinoma, Endothelial cell, Angiogenesis, Cancer stem cell, Tumor-initiating cell, CD31,
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Conventional models of carcinogenesis posit that tumor vas-
culature develops in response to factors produced by neo-
plastic tissues (such as vascular endothelial growth factor)
that elicit the sprouting of new blood vessels from surround-
ing pre-existing “normal” vasculature while also promoting
the recruitment and differentiation of bone marrow-derived
vascular progenitor cells [1]. This concept has recently been
challenged by the cancer stem cell (CSC) model, which sug-
gests that tumors are sustained by a distinct population of* Correspondence: anand.ghanekar@uhn.ca
1Toronto General Research Institute, University Health Network, Toronto,
ON, Canada
2Department of Surgery, University Health Network, Toronto, ON, Canada
Full list of author information is available at the end of the article
© 2013 Ghanekar et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the orcancer cells with stem cell-like properties that self-renew and
are also capable of generating the full repertoire of cell types
found within tumors, including those contributing to tumor
vasculature [2]. Most notably, two recent reports focused on
glioblastoma have provided compelling evidence that
intratumoral vascular endothelium arises from CSCs [3,4].
Hepatocellular carcinoma (HCC) is one of the five
most common cancers worldwide, and the third most
common cause of cancer death [5]. Early-stage HCC
confined to the liver is amenable to potentially curative
therapies such as ablation, partial hepatic resection, or
liver transplantation, though disease recurrence is com-
mon [6]. Patients with more advanced disease have a
median survival less than one year due to the inefficacyral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vascularized tumor, and this characteristic is exploited as
a key diagnostic criterion on radiological imaging [8].
Pathways and mediators regulating angiogenesis and
neovascularization are thus recognized to play an import-
ant role in the development and progression of HCC and
have emerged as attractive targets in the development of
new therapies against this lethal disease [9].
Several studies suggest that CSCs, functionally assayed
by their operational role as tumor-initiating cells (TICs),
play a role in the pathogenesis of human HCC. Many dif-
ferent subpopulations of cells with tumor-initiating cap-
acity in xenograft models have been isolated from HCC
cell lines and patient tissues in recent years but their rela-
tive contributions to various aspects of HCC pathobiology
remain to be clearly defined or understood [10-13]. Des-
pite important implications for the correct targeting of
new therapies against tumor vessel formation in HCC, the
specific question of whether HCC vasculature arises from
TICs or from surrounding tissues through “conventional”
models of angiogenesis remains unexplored.
In this study, we sought to determine whether intratumoral
endothelial cells in human HCC arise from TICs or from
the surrounding non-cancerous tissue. We studied human
HCC in biologically relevant in vivo models chosen for
their ability to propagate tumors from single cells defined
by their tumor-initiating function rather than a specific
phenotypic cell surface marker. We first studied HCC
tumor nodules generated in the livers of immunodeficient
mice following intrasplenic injection of human HCC cells
from established cell lines as well as patient tumors. We
then examined human HCC tumors that developed in
sex-mismatched liver allografts of patients who had
undergone liver transplantation for treatment of HCC.
We demonstrate that in both settings, endothelial cells
(ECs) in human HCC do not arise from TICs.
Methods
Ethical approvals were obtained from the University
Health Network Research Ethics Board (Protocol #08-
0697-TE) and Animal Care Committee (Animal Use
Protocol #1595). Human tissues were obtained with
written consent from patients.
Human HCC cell lines
HepG2 cells were obtained from ATCC (catalog no. HB-
8065) and grown in culture according to the supplier’s
instructions. Instead of fetal bovine serum, growth medium
was supplemented with 15% KnockOut SR XenoFree CTS
serum replacement (Invitrogen). Huh7 cells were a kind gift
from Dr. Paolo Parini (Karolinska Institute, Sweden) and were
grown in DMEM/F12 media (Invitrogen) supplemented
with 1X GlutaMAX (Invitrogen) and 15% KnockOut
SR XenoFree CTS serum replacement (Invitrogen). Cellswere harvested for xenografting with Accutase (StemCell
Technologies) according to the manufacturer’s instructions.
Patient samples and preparation of tumor cell
suspensions
HCC samples were obtained from patients undergoing
surgery. Clinical data were obtained by chart review.
Fresh tumor samples of approximately 1 cm3 were taken
from the viable periphery of tumors within 30 minutes
of resection and transferred on ice to the laboratory.
Samples were sectioned for fixation in formalin, preser-
vation in RNAlater (Invitrogen), or immediate digestion.
Bulk tumor cell suspensions were prepared from patient
samples by digestion of minced tumor fragments with
200 units/mL of type IV Collagenase (Sigma) and 0.8
units/mL of dispase II (Stem Cell Technologies) for 30-
60 minutes at 37°C in an equal mixture of Dulbecco’s
Modified Eagle Medium (DMEM) and F12 medium
(both from Invitrogen), passage through a 70 μm cell
strainer (BD Biosciences), centrifugation, and lysis of
red blood cells using RBC lysis buffer (eBioscience).
Human CD45+ cells and dead cells were excluded by
fluorescence activated cell sorting on a FACSAria II
cell sorter (BD Biosciences) after staining with anti-
human CD45 PE-Cy7 (BD Biosciences) and Live/Dead
Fixable Violet Dead Cell Stain Kit (Invitrogen) as per
the manufacturer’s instructions; the viable CD45- frac-
tion was then used for xenografting.
Xenografts
6-8 week old female NSG mice (non-obese diabetic se-
vere combined immunodeficiency interleukin 2 receptor
gamma chain null) (Jackson Laboratory) were anesthe-
tized with inhalational isoflurane. Using aseptic surgical
technique, a left subcostal incision was made and the
spleen exposed. 106 HCC cells in 30 μL of cold Matrigel
(BD Biosciences) were injected into the lower pole of the
spleen using a 29-gauge needle. Upon removal of the
needle the lower pole of the spleen was ligated with a
silk ligature and the abdominal incision then closed with
sutures. After recovery from surgery, animals were observed
for 90 days and then sacrificed. Tissues were fixed in forma-
lin or preserved in RNAlater. The xenografts analyzed in
this study were generated from two different human HCC
cell lines (HepG2 and Huh7) as well as from primary cells
isolated from three different HCC specimens originating
from three distinct patients. Xenografts were generated in
duplicate in different mice from each cell line or patient
sample and analyzed independently as described below.
Reverse transcription polymerase chain reaction (RT-PCR)
Ribonucleic acid (RNA) was isolated using TRIzol
(Invitrogen) from tissues stored in RNAlater and then
analyzed as previously described [14].
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Formalin-fixed, paraffin-embedded tissues were utilized.
Hematoxylin and eosin (H & E) stains were performed
using standard techniques. For immunohistochemistry
on human HCC xenografts and mouse liver tissue, dewaxed
sections were blocked with 3% hydrogen peroxide, avidin/
biotin blocking kit (Vector Labs), and 10% normal serum
from the secondary antibody species, then incubated at
room temperature with primary antibody overnight as fol-
lows: monoclonal mouse anti-human CD31 (Dako), poly-
clonal PECAM-1 antibody which recognizes both mouse
and human CD31 (Santa Cruz), or monoclonal mouse anti-
mouse H-2K (BD Biosciences). This was followed by biotin
labeled secondary antibody (Vector Labs) for 30 minutes
and horseradish peroxidase-conjugated ultrastreptavidin
labeling reagent (ID Labs) for 30 minutes. Color was
developed with DAB solution (Dako). Sections were
counterstained with Mayer’s hematoxylin, dehydrated
and mounted in Permount (Fisher). For analysis of hu-
man HCC specimens resected from sex-mismatched
liver allografts, fluorescent immunohistochemistry was
performed first using monoclonal mouse anti-human
CD34 (Dako) or polyclonal goat anti-CD31 (Santa Cruz),
in combination with monoclonal mouse anti-human
CD45 (Dako) followed by Cy5 conjugated goat anti-
rabbit or goat-anti-mouse IgG (Jackson ImmunoResearch
Laboratories) or by Cy3 conjugated goat anti-mouse
CD45 antibody (Jackson) according to manufacturer’s
protocols. Counterstaining was performed with DAPI
(Vector Labs). Images were captured with a CV-M4 +
CL progressive scan monochrome camera (JAI) on a
Zeiss Imager M1 using Metasystems workstation and
ISIS software programs. Coordinates for all images were
recorded. Slides were then washed in PBS, immersed
in 100% ethanol and air dried. Fluorescence in situ
hybridization (FISH) for X and Y chromosomes was
performed using CEPX(DXZ1) SpO and CEPY(DYZ1)
SpG Alpha Satellite DNA probes (Abbott Labs) as per
the manufacturer’s recommendations. Dual color probes
and target DNA were co-denaturated at 75°C for 5 minutes
on HyBRITE followed by overnight hybridization at 37°C.
Slides were washed, air dried and counterstained with
DAPI. Using recorded coordinates, fields matching immu-
nohistochemistry images were recaptured to evaluate stain-
ing of X and Y chromosomes in cells of interest by
counting signals in at least 100 non-overlapping intact cells.
Results and discussion
We focused on generating xenografts within the murine
liver in order to study tumor vasculature in the microenvir-
onment most relevant for human HCC pathobiology. By
injecting human HepG2 and Huh7 HCC cell lines or pri-
mary CD45- bulk HCC cells isolated from patient tumors
into the spleens of recipient NSG mice, we generatedintrahepatic human HCC xenografts consisting of discrete
nodules (Figure 1A) that presumably originated from single
tumor-initiating cells (TICs) that had migrated into the
mouse liver via the splenic vein and portal circulation [15].
We analyzed these nodules by RT-PCR to confirm the ex-
pression of liver cell markers typical of HCC (Figure 1B),
and found that the xenografts demonstrated histologic fea-
tures typical of HCC including hepatocyte-like cells with
nuclear atypia and high nuclear:cytoplasmic ratio, absence
of portal tracts, and distorted trabeculae with increased
thickness of hepatocellular plates (Figure 1D, 1E, and 1F).
When patient-derived HCC cells were used, the xenograft
histology was similar to the original patient tumor
(Figure 1C and 1D). We have utilized this approach
successfully with HCC samples from several patients
with reproducible results [16].
Because of the likelihood that cell surface marker pheno-
types of TICs vary between cell lines and among different
patient tumors, we utilized the approach of intrasplenic in-
jection of bulk tumor cells in order to select for HCC cells
with tumor-initiating function in an unbiased manner ra-
ther than purify specific populations from the wide variety
of putative HCC TICs described in the literature. By
injecting cells in the spleen rather than directly into
the mouse liver, we also hoped to avoid the potentially
confounding contributions to xenograft vasculature
from human ECs isolated along with bulk tumor cells
from enzymatically digested HCC specimens. Further-
more, we believe this indirect approach yields intrahepatic
tumor nodules derived from single HCC cells rather than
from cell aggregates that might yield tumors from bulk
tumor cell suspensions implanted directly into the mouse
liver.
To determine whether intratumoral ECs were derived
from TICs, we used immunohistochemistry to ascertain
whether the vasculature of human HCC xenograft nod-
ules in the murine liver was of mouse or human origin.
Because initial staining for the mouse histocompatibility
molecule H-2K clearly identified structures with vascular
morphology within xenografts (not shown), we stained more
specifically for murine and human CD31 (PECAM-1), an
endothelial cell marker. As shown in Figure 2A, immunohis-
tochemical staining of patient-derived HCC xenografts
within the murine liver using a polyclonal antibody
recognizing mouse and human CD31 demonstrated endo-
thelial cells in sinusoid-like vascular structures. In con-
trast, as shown in Figure 2B, immunohistochemical
staining of corresponding tissue sections using a monoclo-
nal antibody against human CD31 was negative, suggesting
that ECs in the xenografts were of mouse origin. Similar
staining patterns with the two antibodies were observed in
corresponding sections of intrahepatic xenografts gener-
ated from Huh7 cells (Figure 2C and 2D) and HepG2
cells (Figure 2E and 2F), corroborating the findings in
Figure 1 Intrahepatic human HCC xenografts in immunodeficient mice. A) Representative image of a murine liver with discrete human HCC
nodules that formed after intrasplenic injection of primary human HCC cells isolated from a surgical resection specimen; similar nodules were also
generated after injection of HepG2 and Huh7 human HCC cell lines. B) Representative RT-PCR analysis of a xenograft demonstrates expression of
several transcripts typical of human liver tissue (composite image; ALB - albumin, AFP - alphafetoprotein, AAT - alpha-1-antitrypsin, TAT - tyrosine
aminotransferase, TDO - tryptophan-2,3-dioxygenase, G6P - glucose-6-phosphate dehydrogenase, CK8/18/19 - cytokeratin 8/18/19, GAPDH -
glyceraldehyde phosphate dehdrogenase). C) Histopathology of a resected patient tumor demonstrates typical features of HCC including
hepatocyte-like cells with nuclear atypia and high nuclear:cytoplasmic ratio, absence of portal tracts, and distorted trabeculae with increased
thickness of hepatocellular plates (H & E stain, x200). D) Section of murine liver demonstrating normal murine liver tissue (top right)
adjacent to intrahepatic human HCC xenograft that closely resembles the corresponding original parent tumor shown in panel C (H & E
stain, x200). E) Histopathology of intrahepatic xenograft generated from Huh7 cells (H & E stain, x200). F) Histopathology of intrahepatic
xenograft generated from HepG2 cells (H & E stain, x200).
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that intratumoral ECs in human HCC xenografts do not
arise from the human TICs but by vessel ingrowth from
the surrounding normal murine liver.
To validate this observation directly in primary human
HCC tissues, we sought to study patients in whom the
origin of intratumoral ECs could be clearly distinguished
from surrounding malignant epithelial tissue without
complex genetic analyses. Because orthotopic liver trans-
plantation is routinely performed at our institution as
definitive therapy for patients with HCC confined to the
liver [17], we were able to identify three highly unique
patients who had received liver allografts from sex-
mismatched organ donors, subsequently developed a
new HCC within the transplanted liver, and then hadthis recurrent HCC resected from the allograft. All of
the patients identified were male and, following complete
removal of their native livers, had received liver allografts
from deceased organ donors who were female. The first
patient underwent liver transplantation at age 56 for hepa-
titis C cirrhosis and a 5 cm moderately differentiated
HCC; three years later, he underwent resection of a 9 cm
moderately differentiated HCC in the right lobe of the
liver allograft. The second patient underwent liver trans-
plantation at age 66 for hepatitis C cirrhosis complicated
by moderately differentiated multifocal HCC; he required
resection of an 18 cm moderately differentiated HCC in
the right lobe of the liver three years after transplantation.
The third patient underwent liver transplantation at age
56 for hepatitis B cirrhosis and moderately differentiated
Figure 2 CD31 staining demonstrates that ECs in human HCC xenografts within the mouse liver are of mouse rather than human origin.
A) Representative immunohistochemical staining with a polyclonal antibody recognizing mouse and human CD31 demonstrates endothelial cells in
sinusoid-like structures (arrows) within patient-derived human HCC xenografts in the murine liver (x200). B) Immunohistochemical staining of the same
section as in Panel A with a monoclonal antibody against human CD31 is negative (x200), suggesting that ECs in the xenografts are of mouse origin.
Similar staining patterns with the two antibodies are observed in intrahepatic xenografts generated from Huh7 cells (Panel C – polyclonal anti-mouse/human
CD31, and Panel D – monoclonal anti-human CD31) and HepG2 cells (Panel E – polyclonal anti-mouse/human CD31, and Panel F – monoclonal anti-human
CD31) (all x100). G) Positive control staining of murine kidney with polyclonal anti-CD31 demonstrates expected pattern of positivity of the glomerular
endothelial cells (x200). H) Positive control staining of human kidney with monoclonal antibody against human CD31 demonstrates expected pattern of
positivity of glomerular ECs verifying activity of the antibody used in Panels B, D, and F (x200). Staining of murine kidney with the monoclonal antibody
against human CD31 was negative (not shown), confirming that this antibody is specific for human CD31.
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ately differentiated HCC in the left lobe of the liver allo-
graft three years after transplantation.
Figure 3 illustrates representative features of the original
and recurrent HCCs from one of the patients. The axial
computed tomography image in Figure 3A demonstrates a
hypervascular lesion consistent with HCC within a patient’scirrhotic native liver. The histopathology of the lesion,
which is consistent with HCC, is shown in Figure 3B.
The axial magnetic resonance image in Figure 3C dem-
onstrates a large hypervascular lesion consistent with
recurrent HCC within the liver allograft of the same
patient. The histopathology of this lesion following re-
section from the liver allograft is shown in Figure 3D,
Figure 3 HCC recurrences in liver allografts of patients who underwent orthotopic liver transplantation for treatment of HCC. A) Axial
computed tomography image demonstrating a hypervascular lesion (arrow) consistent with HCC within a patient’s cirrhotic native liver.
B) Histopathology of lesion in explanted liver demonstrates features consistent with HCC (H & E stain, x100). C) Axial magnetic
resonance image of large hypervascular lesion (arrow) within the liver allograft consistent with recurrent HCC. D) Histopathology of
lesion resected from liver allograft demonstrates features consistent with HCC (H & E stain, x100).
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recurrent tumors were discrete lesions within the liver
allografts, and not tumors on the liver surface or in the
perihepatic tissues that might have resulted from direct
tumor seeding into the operative field at the time of
transplantation surgery. The appearance of the recur-
rent HCCs suggests that they either developed as de
novo malignancies from the liver allograft tissue itself,
or from implantation and growth of circulating tumor-
initiating cells derived from the patient’s original tumor
that persisted in the patient’s lymphatic or vascular system
following native total hepatectomy.
Using immunofluorescent staining for CD31 (PECAM-1)
and CD34, a marker of sinusoidal ECs in HCC [18], in
combination with fluorescence in situ hybridization (FISH)
for the X and Y chromosomes, we sought to determine
which compartments of the recurrent HCCs had originated
from the donor as opposed to the recipient. Figure 4A
demonstrates representative immunofluorescence staining
for CD31 and CD45 that identifies ECs and leukocytes
within an HCC recurrence that arose in a male patient who
received a liver allograft from a female donor. Figure 4B
shows the FISH overlay image of the corresponding field to
that shown in Panel A, illustrating that the nuclei of ECs
have only X chromosomes while leukocytes and tumor cells
have both X chromosomes and Y chromosomes. Figure 4C
demonstrates representative immunofluorescence staining
for CD34, which identifies sinusoidal ECs within arecurrent HCC. Figure 4D shows the FISH overlay
image of the corresponding field to that shown in
Panel C, illustrating that EC nuclei have only X chro-
mosomes while surrounding tumor cells have both X
chromosomes and Y chromosomes. Taken together,
Figure 4 demonstrates that CD31+ and CD34+ ECs
within the tumor tissue only demonstrate presence of
the X chromosome, while the surrounding epithelial
cells constituting the bulk of the HCC demonstrate
staining for both the X and Y chromosomes. Because
the ECs within the recurrent HCCs have an XX pheno-
type consistent with the female origin of the liver allo-
graft, this suggests that the vascularization of the
recurrent HCCs occurred by ingrowth of vessels from
the surrounding liver allograft rather than from endo-
thelial differentiation of TICs (in which case the ECs
would be XY). In addition, because the tumor cells mak-
ing up the bulk of the HCCs within the transplanted livers
share the sex of the recipients (XY) rather than the donors
(XX), this observation suggests that these HCCs were not
de novo malignancies that arose by transformation of he-
patocytes within the allograft (in which case the bulk of
the tumor cells would be XX), but rather must have arisen
from circulating TICs derived from the recipient’s original
HCC.
Limitations of this study include the ability of patient-
derived xenograft models to accurately recapitulate all
aspects of human cancer pathobiology, which have been
Figure 4 Endothelial cells within HCC recurrences in patients who received sex-mismatched liver allografts originate from the donor
allograft rather than from tumor cells. A) Representative immunofluorescence staining for CD31 (red) and CD45 (green) identifies ECs (red
arrows) and leukocytes (green arrows) within an HCC recurrence that arose in a male patient who received a liver allograft from a female donor
(x400). B) Fluorescence in situ hybridization (FISH) overlay image of field corresponding to that shown in Panel A demonstrating that nuclei of
endothelial cells (red arrows) have only X chromosomes (red dots) while leukocytes (green arrows) and tumor cells have both X chromosomes
and Y chromosomes (green dots) (x400). C) Representative immunofluorescence staining for CD34 (green) identifies sinuisoidal ECs (arrows)
within a recurrent HCC (x400). D) FISH overlay image of a field corresponding to that shown in Panel C demonstrating that endothelial cell nuclei
(arrows) have only X chromosomes (red dots) while surrounding tumor cells have both X chromosomes and Y chromosomes (green dots) (x400).
The XY phenotype of the tumor cells also confirms that the HCCs occurring in the liver allografts are recurrences of the male patient’s original
tumor (XY) rather than malignancies arising from de novo transformation of hepatocytes in the XX liver allograft.
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ine host and incompatibilities between murine and hu-
man factors in the tumor microenvironment [19]. In
order to prevent liver allograft rejection, the patients
with HCC recurrences that we studied to validate our
observations in xenografts were also receiving immuno-
suppressive therapy, which is known to facilitate cancer
development and progression [20]. In addition, all of the
resected HCC recurrences that we studied by FISH were
moderately differentiated tumors; due to the extremely
unique characteristics of the patients from whom these
samples originated, we were unable to study specimens
that were either well differentiated or poorly differenti-
ated. Although it is possible that endothelial cell origins
are different in such tumors, we feel that the observa-
tions presented in this study provide valuable insights
into the pathobiology of human HCC.
Conclusions
Taken together, our observations from two unique, bio-
logically relevant, high-fidelity in vivo models of functional
tumor-initiation strongly suggest that human HCC con-
forms to conventional models of tumor angiogenesis inwhich the tumor vasculature is recruited from surround-
ing “normal” tissues rather than generated through differen-
tiation of TICs. This supports the notion that the biology of
TICs may vary between different cancers, and that the ob-
servations prominently reported concerning glioblastoma
may be specific to that disease. Reports validating a TIC ori-
gin of ECs in other cancer types have yet to emerge in the
literature. While there is increasing attention to the potential
contributions of CSCs/TICs to the pathobiology of human
HCC and other tumors, our observations demonstrate that
the roles of these cells likely vary between different cancers.
The data presented herein firmly support the importance
and relevance of many ongoing research efforts targeting
pathways and mechanisms of tumor angiogenesis and
neovascularization as they are currently understood
[21] in order to develop novel therapeutic strategies
for this frequently lethal cancer.Abbreviations
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